Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Diarrhea 1Carcinoma, Medullary 1

Interventions

Cyclophosphamide 37Gemcitabine 31Paclitaxel 27Cisplatin 27Carboplatin 27Capecitabine 27camrelizumab 24Nivolumab 23apatinib 22Oxaliplatin 21fludarabine 20Radiotherapy 20toripalimab 17Immunotherapy, Adoptive 17Drug Therapy 17pembrolizumab 16Docetaxel 16Dexamethasone 15Bevacizumab 15N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 14Injections 14tislelizumab 13Temozolomide 13Rituximab 13Cetuximab 13Irinotecan 12130-nm albumin-bound paclitaxel 11anlotinib 10Fluorouracil 10Trastuzumab 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Unknown × Calcium Aluminosilicate × Clear all
NCT01739634 2012-12-03

The Efficacy of CASAD in Patients With Diarrhea Related to Medullary Thyroid Cancer

Salient Pharmaceuticals Incorporated

Phase 1/2 Unknown
10 enrolled

Diarrhea, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡